

Lauren Peter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3403763/publications.pdf>

Version: 2024-02-01

31
papers

8,041
citations

236925

25
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

14560
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609. | 5.6 | 14 |
| 2 | Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nature Medicine</i> , 2022, 28, 1288-1296. | 30.7 | 44 |
| 3 | Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, . | 7.1 | 8 |
| 4 | Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. <i>Nature Medicine</i> , 2021, 27, 515-525. | 30.7 | 248 |
| 5 | Immunogenicity of the Ad26.COVID.S Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535. | 7.4 | 260 |
| 6 | A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine. <i>Annals of Internal Medicine</i> , 2021, 174, 585-594. | 3.9 | 44 |
| 7 | Low-dose Ad26.COVID.S protection against SARS-CoV-2 challenge in rhesus macaques. <i>Cell</i> , 2021, 184, 3467-3473.e11. | 28.9 | 49 |
| 8 | Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. <i>Journal of Virology</i> , 2021, 95, e0040421. | 3.4 | 34 |
| 9 | Correlates of protection against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2021, 590, 630-634. | 27.8 | 995 |
| 10 | Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , 2021, 27, 1718-1724. | 30.7 | 39 |
| 11 | Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020, 183, 185-196.e14. | 28.9 | 25 |
| 12 | Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <i>Nature</i> , 2020, 586, 583-588. | 27.8 | 765 |
| 13 | Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1061-1070. | 9.1 | 36 |
| 14 | SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science</i> , 2020, 369, 812-817. | 12.6 | 789 |
| 15 | DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <i>Science</i> , 2020, 369, 806-811. | 12.6 | 978 |
| 16 | Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika-specific antibodies. <i>American Journal of Reproductive Immunology</i> , 2020, 84, e13288. | 1.2 | 7 |
| 17 | Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020, 26, 498-501. | 30.7 | 43 |
| 18 | Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP) Tj ETQq0 0.0 rgBT /Overlock 10 | | |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , 2018, 218, 633-644. | 4.0 | 35 |
| 20 | First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. <i>PLoS ONE</i> , 2018, 13, e0205139. | 2.5 | 32 |
| 21 | Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. <i>Nature</i> , 2018, 563, 360-364. | 27.8 | 246 |
| 22 | Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018, 392, 232-243. | 13.7 | 269 |
| 23 | An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature</i> , 2017, 547, 217-221. | 27.8 | 2,112 |
| 24 | Rapid Inflammasome Activation following Mucosal SIV Infection of Rhesus Monkeys. <i>Cell</i> , 2016, 165, 656-667. | 28.9 | 144 |
| 25 | Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. <i>Science</i> , 2016, 353, 1045-1049. | 12.6 | 129 |
| 26 | Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys. <i>Nature</i> , 2016, 540, 284-287. | 27.8 | 246 |
| 27 | Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention. <i>Annals of Internal Medicine</i> , 2016, 164, 313. | 3.9 | 70 |
| 28 | Induction of HIV-1-Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans. <i>Journal of Infectious Diseases</i> , 2015, 211, 518-528. | 4.0 | 60 |
| 29 | First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002). <i>Journal of Infectious Diseases</i> , 2014, 210, 1052-1061. | 4.0 | 25 |
| 30 | Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001). <i>Journal of Infectious Diseases</i> , 2013, 207, 248-256. | 4.0 | 98 |
| 31 | First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001). <i>Journal of Infectious Diseases</i> , 2013, 207, 240-247. | 4.0 | 144 |